1-Fluoro-5-iodo-4-methoxy-2-methylbenzene | 1117893-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Fluoro-5-iodo-4-methoxy-2-methylbenzene
• CAS: 1117893-12-5
• 化学式: C₈H₈FIO
• 分子量: 266.054
• InChiKey: HSXRVCIYQHLHAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Fluoro-5-iodo-4-methoxy-2-methylbenzene 在 三乙基硅烷 、 正丁基锂 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  Optimization of Replication, Transcription, and Translation in a Semi-Synthetic Organism

  摘要：

  Previously, we reported the creation of a semi synthetic organism (SSO) that stores and retrieves increased information by virtue of stably maintaining an unnatural base pair (UBP) in its DNA, transcribing the corresponding unnatural nucleotides into the codons and anticodons of mRNAs and tRNAs, and then using them to produce proteins containing noncanonical amino acids (ncAAs). Here we report a systematic extension of the effort to optimize the SSO by exploring a variety of deoxy- and ribonucleotide analogues. Importantly, this includes the first in vivo structure-activity relationship (SAR) analysis of unnatural ribonucleoside triphosphates. Similarities and differences between how DNA and RNA polymerases recognize the unnatural nucleotides were observed, and remarkably, we found that a wide variety of unnatural ribonucleotides can be efficiently transcribed into RNA and then productively and selectively paired at the ribosome to mediate the synthesis of proteins with ncAAs. The results extend previous studies, demonstrating that nucleotides bearing no significant structural or functional homology to the natural nucleotides can be efficiently and selectively paired during replication, to include each step of the entire process of information storage and retrieval. From a practical perspective, the results identify the most optimal UBP for replication and transcription, as well as the most optimal unnatural ribonucleoside triphosphates for transcription and translation. The optimized SSO is now, for the first time, able to efficiently produce proteins containing multiple, proximal ncAAs.

  DOI：

  10.1021/jacs.9b02075
• 作为产物：
  描述：

  4-氟-3-甲基苯甲醚 在 碘 、 silver nitrate 作用下， 以 甲醇 为溶剂， 以73%的产率得到1-Fluoro-5-iodo-4-methoxy-2-methylbenzene
  参考文献：
  名称：

  Seo, Young Jun; Hwang, Gil Tae; Ordoukhanian, Phillip, Journal of the American Chemical Society, 2009, vol. 131, p. 3246 - 3252

  摘要：

  DOI：

文献信息

• REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS
  申请人：The Scripps Research Institute

  公开号：US20200392550A1

  公开（公告）日：2020-12-17

  Disclosed herein are compositions, methods, cells, engineered microorganisms, and kits for increasing the production of proteins or polypeptides comprising one or more unnatural amino acids. Further provided are compositions, cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism.

  本文揭示了一种用于增加含有一个或多个非天然氨基酸的蛋白质或多肽的生产的组合物、方法、细胞、工程微生物和试剂盒。此外，还提供了一种用于增加编码非天然氨基酸的非天然核酸在工程细胞或半合成生物体中的保留的组合物、细胞、工程微生物和试剂盒。
• [EN] IL-2 CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS D'IL-2 ET MÉTHODES D'UTILISATION DE CEUX-CI
  申请人：SYNTHORX INC

  公开号：WO2020163532A1

  公开（公告）日：2020-08-13

  Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
• [EN] IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES<br/>[FR] POLYTHÉRAPIE PAR IMMUNO-ONCOLOGIE AVEC DES CONJUGUÉS D'IL-2 ET DES ANTICORPS ANTI-EGFR
  申请人：SYNTHORX INC

  公开号：WO2021263026A1

  公开（公告）日：2021-12-30

  Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
• [EN] IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB<br/>[FR] POLYTHÉRAPIE IMMUNO-ONCOLOGIQUE AVEC DES CONJUGUÉS D'IL-2 ET DU PEMBROLIZUMAB
  申请人：[en]SYNTHORX, INC.

  公开号：WO2022076853A1

  公开（公告）日：2022-04-14

  Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with pembrolizumab.
• [EN] HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB<br/>[FR] POLYTHÉRAPIE CONTRE LE CANCER DE LA TÊTE ET DU COU COMPRENANT UN CONJUGUÉ D'IL-2 ET DU PEMBROLIZUMAB
  申请人：[en]SYNTHORX, INC.

  公开号：WO2022256534A1

  公开（公告）日：2022-12-08

  Disclosed herein are methods for treating head and neck squamous cell carcinoma (HNSCC) in a subject in need thereof, comprising administering IL-2 conjugates in combination with one or more additional agents.